VYNE Therapeutics Inc.
VYNE · Price history
Company & revenue
About VYNE Therapeutics Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis.
How they make money
VYNE Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate commercial revenue. Its business model focuses on the research and development of small molecule bromodomain and extra-terminal domain (BET) inhibitors to treat chronic inflammatory and immune-mediated conditions, relying on capital raises and potential future licensing or partnership agreements to fund operations.
Products & services
The company is developing a pipeline of BET inhibitor product candidates, including VYN202, for the treatment of various immune-mediated diseases.
Brands & revenue mix
Lead BET inhibitor product candidate currently in clinical development.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes various third-party contract research organizations to conduct clinical trials and non-clinical studies; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Tay Therapeutics Ltd. — The company holds exclusive worldwide rights to research, develop, and commercialize BET inhibitor products licensed from Tay Therapeutics Ltd.Source
Strengths
- Exclusive worldwide rights to a library of BET inhibitor small moleculesSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
27
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
42
Weak
Financial Strength
65
Business Quality / Moat
13
Management
40
Growth Quality
73
Risk / Durability
0
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
38
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
44/100
Building Historical Record
Model Score 44/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for VYNE
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can VYNE maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can VYNE fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is VYNE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for VYNE to reach sustainable profitability?
- •What future growth or profitability would be needed to justify VYNE's current valuation?
Essential Investment Snapshot
Wall Street Score
27
Opportunity Score
38
Market Cap
$19.1M
P/E Ratio
-0.0
EPS
$-636.98
52-Week High
$74.47
52-Week Low
$14.03
Beta
2.01
Analyst Target
$5.75
Shares Outstanding
855K
Total Revenue
$955K
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$0.03
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Community Sentiment
0 active · 0 total callsNo personal call yet on VYNE.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Exclusive worldwide rights to a library of BET inhibitor small molecules.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and accumulated deficit.
- −Dependence on third-party clinical trial providers and regulatory approval success.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
27
Oct 1, 2026
Change
Unchanged
Current Score
27
Oct 26, 2026
Category Changes
VYNE score was unchanged.
Projected Score
Projected Score
33
Projected Change
+6.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 6.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$28.56
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $955K | $570K | $501K | $424K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $6K | $23K | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $949K | $547K | $501K | $424K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $28.3M | $19.2M | $30.9M | $16.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $19.2M | $11.1M | $13.2M | $13.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $47.5M | $30.3M | $44.1M | $29.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$45.7M | -$26.7M | -$39.8M | -$27.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$46.6M | -$29.7M | -$43.6M | -$29.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$42.7M | -$26.7M | -$39.8M | -$27.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $8K | $4K | $4K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$42.2M | -$26.5M | -$39.8M | -$28.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-636.98 | $-31.00 | $-47.00 | $-138.50 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 42.8K | 855K | 852K | 205K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 42.8K | 855K | 852K | 205K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$570000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$619.29
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-100.0%
Cash Change
-99.9%
Margin Change
+3694.4 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels, net income margin. Pressure indicators included cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 726.1%. EPS increased 9427.5%. Cash declined 99.9%. Total debt declined 100.0%. Net income margin improved by 3694.4 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
No news available for VYNE.
Rumor Mill · VYNE
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial